Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.
Vlado Perkovic, MBBS, PhD
Advertisement
Vlado Perkovic is Dean and Scientia Professor of Medicine at UNSW Sydney. He is also a Professorial Fellow at The George Institute and a Staff Specialist in Nephrology at the Royal North Shore Hospital in Sydney.
Articles by Vlado Perkovic, MBBS, PhD
1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.
FLOW/SELECT suggest. GLP-1 receptor agonists may protect kidneys beyond glucose control
Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data.
From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.
Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Identifying Patients for Systemic Therapy: Beyond
2
Skin of Color Savvy: Patient Power—Voices Driving Change in Skin of Color Care
3
Clinical Burden and Unmet Need in Familial Chylomicronemia Syndrome
4
What Referring Physicians Should Know: Avoiding the "Wait and See" Approach
5